01—Abstract
Summary
Summary of the 8-K filed January 13, 2025. Cited figures are marked; the original filing is the authoritative source.
Danaher Corporation (NYSE: DHR) filed this Form 8-K on January 13, 2025, furnishing a preliminary update on its fourth quarter 2024 results ahead of CEO Rainer M.
Blair's presentation at the J.P. Morgan Healthcare Conference on January 14, 2025. The company estimates Q4 2024 total (GAAP) revenue grew in the low-single-digit percent range year-over-year, while non-GAAP core revenue was expected to be essentially flat.
Management said core revenue came in above its previously guided low-single-digit percent decline, with Bioprocessing performing in line with expectations, Diagnostics slightly above expectations (led by higher respiratory demand at Cepheid), and Life Sciences modestly better than anticipated, driven by instrumentation. The company reaffirmed that its Q4 adjusted operating profit margin is expected to be consistent with prior guidance, with better-than-expected operational performance offset by foreign exchange headwinds.
The presentation also provided a portfolio overview: 2024E total revenue of roughly $24 billiona across Diagnostics (~$9.8B), Life Sciences (~$7.3B), and Bioprocessing (~$6.8B), with about 80% recurring revenue and a stated long-term high-single-digit core revenue growth target for Bioprocessing and Life Sciences. Investors should note that these are estimates furnished rather than filed, and that the full Q4 and FY2024 earnings release is scheduled for January 29, 2025.
02—Key points
Key Highlights
- Q4 2024 GAAP revenue estimated to grow in the low-single-digit percent range year-over-year.
- Q4 2024 non-GAAP core revenue expected to be essentially flat, beating prior guidance of a low-single-digit percent decline.
- Diagnostics slightly above expectations, led by higher respiratory demand at Cepheid; Bioprocessing in line; Life Sciences modestly better, driven by instrumentation.
- Q4 adjusted operating profit margin expected to be consistent with prior guidance, as operational outperformance offset FX headwinds.
- 2024E total revenue of approximately $24 billion, with Diagnostics (~$9.8B), Life Sciences (~$7.3B), and Bioprocessing (~$6.8B).
- Approximately 80% of revenue is recurring, supported by a razor/razor-blade model and an extensive installed base.
- Full Q4 and FY2024 earnings call scheduled for January 29, 2025, at 8:00 a.m. ET.
03—Questions
Frequently Asked Questions
Did Danaher's Q4 2024 core revenue meet expectations?
Yes, and it modestly exceeded them. Danaher expects Q4 2024 non-GAAP core revenue to be essentially flat year-over-year, compared with prior guidance for a low-single-digit percent decline. Acquisitions/divestitures reduced reported growth by a low-single-digit percentage, while currency was essentially flat.
What drove the better-than-expected performance?
Management cited higher respiratory demand at Cepheid within Diagnostics, instrumentation strength within Life Sciences, and Bioprocessing performance in line with expectations. Overall operational performance was better than anticipated.
Will the stronger revenue translate into higher margins?
Not necessarily for Q4. Danaher said its adjusted operating profit margin is expected to be consistent with prior guidance, because better-than-expected operational results were offset by foreign exchange headwinds.
What is the scale and mix of Danaher's business?
For 2024E, total revenue is about $24 billion. Diagnostics contributes roughly $9.8 billion, Life Sciences about $7.3 billion, and Bioprocessing (Cytiva) about $6.8 billion. The company states that roughly 80% of revenue is recurring.
When will more detailed results be available?
Danaher will report its fourth quarter and full-year 2024 results and hold its earnings conference call on Wednesday, January 29, 2025, at 8:00 a.m. ET. The figures in this 8-K are preliminary estimates and are furnished, not filed, under Item 2.02.
04—Continue